688621 阳光诺和
已收盘 09-30 15:00:00
资讯
新帖
简况
阳光诺和(688621.SH)：STC008注射液治疗晚期实体瘤的肿瘤恶液质的I期临床试验达成预期目标
智通财经 · 09-28
阳光诺和(688621.SH)：STC008注射液治疗晚期实体瘤的肿瘤恶液质的I期临床试验达成预期目标
阳光诺和（688621）披露诉讼事项进展暨达成和解公告，9月24日股价下跌3.34%
证券之星 · 09-24
阳光诺和（688621）披露诉讼事项进展暨达成和解公告，9月24日股价下跌3.34%
【机构调研记录】圆信永丰基金调研阳光诺和、星徽股份等3只个股（附名单）
证券之星 · 09-23
【机构调研记录】圆信永丰基金调研阳光诺和、星徽股份等3只个股（附名单）
【私募调研记录】途灵资产调研阳光诺和
证券之星 · 09-23
【私募调研记录】途灵资产调研阳光诺和
阳光诺和：9月22日召开业绩说明会，投资者、国联民生证券等多家机构参与
证券之星 · 09-22
阳光诺和：9月22日召开业绩说明会，投资者、国联民生证券等多家机构参与
阳光诺和(688621.SH)签署《ABA001项目合作开发协议》
智通财经 · 09-21
阳光诺和(688621.SH)签署《ABA001项目合作开发协议》
阳光诺和最新公告：BTP0427获药物临床试验批准通知书
证券之星 · 09-16
阳光诺和最新公告：BTP0427获药物临床试验批准通知书
阳光诺和上半年净利转亏 2021上市募5亿国联民生保荐
中金财经 · 09-09
阳光诺和上半年净利转亏 2021上市募5亿国联民生保荐
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
中金财经 · 09-04
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
8月31日阳光诺和涨9.14%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 08-31
8月31日阳光诺和涨9.14%，融通健康产业灵活配置混合A/B基金重仓该股
阳光诺和（688621）2026年中报简析：净利润同比下降118.79%，三费占比上升明显
证券之星 · 08-30
阳光诺和（688621）2026年中报简析：净利润同比下降118.79%，三费占比上升明显
每周股票复盘：阳光诺和（688621）Q2净利下滑144.92%
证券之星 · 08-30
每周股票复盘：阳光诺和（688621）Q2净利下滑144.92%
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
中国财富通 · 08-29
阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发
阳光诺和（688621）发布关于使用部分募集资金向全资子公司增资以实施募投项目的公告，8月28日股价下跌3.66%
证券之星 · 08-28
阳光诺和（688621）发布关于使用部分募集资金向全资子公司增资以实施募投项目的公告，8月28日股价下跌3.66%
图解阳光诺和中报：第二季度单季净利润同比下降144.92%
证券之星 · 08-28
图解阳光诺和中报：第二季度单季净利润同比下降144.92%
阳光诺和(688621)6月30日股东户数0.77万户，较上期减少3.28%
证券之星 · 08-28
阳光诺和(688621)6月30日股东户数0.77万户，较上期减少3.28%
每周股票复盘：阳光诺和（688621）实控人转让5%股份完成过户
证券之星 · 08-16
每周股票复盘：阳光诺和（688621）实控人转让5%股份完成过户
阳光诺和半年报预亏警示：仿创转型下三重经营风险凸显
新浪证券 · 08-14
阳光诺和半年报预亏警示：仿创转型下三重经营风险凸显
股市必读：阳光诺和新发布《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》
证券之星 · 08-14
股市必读：阳光诺和新发布《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》
阳光诺和（688621）披露2025年限制性股票激励计划首次授予部分第一个归属期归属结果公告，8月12日股价上涨3.74%
证券之星 · 08-12
阳光诺和（688621）披露2025年限制性股票激励计划首次授予部分第一个归属期归属结果公告，8月12日股价上涨3.74%
加载更多
公司概况
公司名称：
北京阳光诺和药物研究股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-21
主营业务：
北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是药物发现、药理药效、药学研究、临床研究、生物分析。公司先后获评国家第五批专精特新“小巨人”企业、北京市高新技术企业、北京市知识产权试点单位、北京市专精特新中小企业等多项资质与荣誉。
发行价格：
26.89
{"stockData":{"symbol":"688621","market":"SH","secType":"STK","nameCN":"阳光诺和","latestPrice":71,"timestamp":1790751600000,"preClose":70.95,"halted":0,"volume":1542082,"delay":0,"changeRate":0.0007,"floatShares":112000000,"shares":112000000,"eps":0.4432,"marketStatus":"已收盘","change":0.05,"latestTime":"09-30 15:00:00","open":70.65,"high":72.25,"low":69.6,"amount":110000000,"amplitude":0.0374,"askPrice":71.11,"askSize":10,"bidPrice":71,"bidSize":229,"shortable":0,"etf":0,"ttmEps":0.4432,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":70.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":78.05,"lowLimit":63.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":112000000,"isCdr":false,"pbRate":6.62,"roa":"--","peRate":160.198556,"roe":"--","epsLYR":1.86,"committee":0.68254,"marketValue":7952000000,"turnoverRate":0.0138,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","afterMarket":{"amount":14200,"volume":200,"close":71,"buyVolume":0,"sellVolume":23,"time":1790753637746,"indexStatus":"已收盘 09-30 15:30:00","preClose":70.95},"floatMarketCap":7952000000},"requestUrl":"/m/hq/s/688621","defaultTab":"news","newsList":[{"id":"2670123507","title":"阳光诺和(688621.SH)：STC008注射液治疗晚期实体瘤的肿瘤恶液质的I期临床试验达成预期目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2670123507","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670123507?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:02","pubTimestamp":1790589760,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司全资子公司成都诺和晟泰生物科技有限公司(以下简称“诺和晟泰”)自主研发的STC008注射液(项目代号“STC008”)治疗晚期实体瘤的肿瘤恶液质的I期临床试验达成预期目标。STC008是诺和晟泰基于iCVETide®平台，自主研发的治疗肿瘤恶液质的化学1类多肽新药，通过激活GHSR并启动下游信号传递，最终达到改善肿瘤恶液质患者的体重减轻和厌食的疗效。拟用于治疗非小细胞肺癌、胃癌、胰腺癌、大肠癌等晚期实体瘤的肿瘤恶液质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","MDTX","688621","BMED","IBBJ","PSYK","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669849988","title":"阳光诺和（688621）披露诉讼事项进展暨达成和解公告，9月24日股价下跌3.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669849988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669849988?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:15","pubTimestamp":1790259323,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，阳光诺和报收于72.75元，较前一交易日下跌3.34%，最新总市值为81.48亿元。该股当日开盘74.6元，最高75.76元，最低71.99元，成交额达1.31亿元，换手率为1.6%。近日，北京阳光诺和药物研究股份有限公司发布《关于诉讼事项进展暨达成和解的公告》。公司前期已对应收账款和合同资产全额计提坏账准备，预计该事项对公司当期及期后利润无负面影响，最终影响以实际执行情况为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400041093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669917354","title":"【机构调研记录】圆信永丰基金调研阳光诺和、星徽股份等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2669917354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669917354?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:09","pubTimestamp":1790122157,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月22日披露的机构调研信息，圆信永丰基金近期对3家上市公司进行了调研，相关名单如下：1）阳光诺和 调研纪要：B01注射液为靶向AGT的siRNA药物，采用GalNAc递送系统，用于治疗高血压，已于2026年1月获临床试验受理，现处I期临床阶段。旗下最近一年表现最佳的公募基金产品为圆信永丰科技驱动混合发起A，最新单位净值为2.68，近一年增长87.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300007290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0181","300464","BK0209","BK0077","BK0216","688621","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669733991","title":"【私募调研记录】途灵资产调研阳光诺和","url":"https://stock-news.laohu8.com/highlight/detail?id=2669733991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669733991?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:08","pubTimestamp":1790122133,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月22日披露的机构调研信息，知名私募途灵资产近期对1家上市公司进行了调研，相关名单如下：1）阳光诺和 调研纪要：B01注射液为靶向AGT的siRNA药物，采用GalNAc递送系统，用于治疗高血压，已于2026年1月获临床试验受理，现处I期临床阶段。公司拥有10余条小核酸在研管线，覆盖高血糖、阿尔茨海默症等适应症，并计划募资不超2.4亿元建设核酸药物平台。法定代表人秦怿，公司经营范围包括资产管理、投资管理、实业投资。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026092300007216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669601140","title":"阳光诺和：9月22日召开业绩说明会，投资者、国联民生证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669601140","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669601140?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:01","pubTimestamp":1790085685,"startTime":"0","endTime":"0","summary":"截至2026年半年度报告出具日，该品种正处于I期临床试验阶段。此外，公司核酸管线还广泛覆盖高血糖、阿尔茨海默症、高尿酸及慢性阻塞性肺疾病等高发适应症。2026年7月，阳光诺和与药康生物签署长期战略合作协议，双方联手打造创新药研发新模式。药康生物在实验动物模型领域具有领先优势，阳光诺和则在药物临床前、临床综合研发服务及自主创新药研发方面积累了丰富经验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200040871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1564","BK0276","01456","688621","BK0216","601456","BK1147","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669152156","title":"阳光诺和(688621.SH)签署《ABA001项目合作开发协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669152156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669152156?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:05","pubTimestamp":1789985134,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和 发布公告，公司与江苏万高药业股份有限公司于近期就共同开发ABA001项目事宜达成合作协议并签署相应的《ABA001项目合作开发协议》。根据《ABA001项目合作开发协议》约定，万高药业本期投资5000万元，全部款项仅用于协议产品境内临床试验、研发优化、注册申报、合规运维及项目直接相关支出，不得挪作他用。本次交易旨在充分发挥双方优势，加快推进ABA001的临床开发、注册申报与商业化落地，为临床需求提供更多治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667560466","title":"阳光诺和最新公告：BTP0427获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667560466","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667560466?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:46","pubTimestamp":1789551998,"startTime":"0","endTime":"0","summary":"阳光诺和(688621.SH)公告称，公司及全资子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，在研项目BTP0427的临床试验申请获得批准。BTP0427为化药2类改良型新药，拟用于治疗射血分数降低的慢性心力衰竭，拟定给药频次为每日1次。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600028355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538585","title":"阳光诺和上半年净利转亏 2021上市募5亿国联民生保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538585","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666538585?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:12","pubTimestamp":1788941523,"startTime":"0","endTime":"0","summary":"中国经济网北京9月9日讯 阳光诺和 近期发布2026年半年度报告。2026年上半年，公司实现营业收入4.26亿元，同比下滑27.81%；归属于上市公司股东的净利润-2440.00万元，去年同期为1.30亿元；归属于上市公司股东的扣除非经常性损益的净利润-2507.03万元，去年同期为1.20亿元；经营活动产生的现金流量净额为-5153.21万元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/09/20260909513461.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/09/20260909513461.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260909/32364751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","BK0276","IPOS","BK1564","01456","688621","BK1147","601456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238341","title":"阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238341","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238341?lang=zh_cn&edition=full","pubTime":"2026-09-04 10:12","pubTimestamp":1788487931,"startTime":"0","endTime":"0","summary":"8月28日，阳光诺和(688621)披露2026年半年报，报告期内，公司实现营收4.26亿元。公司战略转型成效渐显：自研1类创新药STC007(瘙痒)完成对外授权，STC008(肿瘤恶液质)临床推进，多个多肽、小核酸、CAR-T管线进入临床阶段；研发投入占营收的比例升至20.54%，技术平台持续升级。公司坚持“CRO服务+自主新药”双轮驱动，以技术转化沉淀长期价值，创新储备与权益分成模式逐渐构筑起未来增长基石。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260904/32359746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663075957","title":"8月31日阳光诺和涨9.14%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075957","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663075957?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:39","pubTimestamp":1788165589,"startTime":"0","endTime":"0","summary":"证券之星消息，8月31日阳光诺和涨9.14%，收盘报68.87元，换手率5.9%，成交量6.61万手，成交额4.53亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100022327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663904817","title":"阳光诺和（688621）2026年中报简析：净利润同比下降118.79%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663904817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663904817?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:18","pubTimestamp":1788041889,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期阳光诺和发布2026年中报。截至本报告期末，公司营业总收入4.26亿元，同比下降27.81%，归母净利润-2440.0万元，同比下降118.79%。本报告期阳光诺和三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达96.28%。去年的净利率为17.22%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于阳光诺和2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010475","title":"每周股票复盘：阳光诺和（688621）Q2净利下滑144.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010475","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010475?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:48","pubTimestamp":1788032891,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，阳光诺和报收于63.1元，较上周的66.01元下跌4.41%。本周，阳光诺和8月24日盘中最高价报68.5元。阳光诺和当前最新总市值70.67亿元，在医疗服务板块市值排名27/51，在两市A股市值排名2429/5211。本周关注点来自业绩披露要点：2026年第二季度归母净利润为-4503.11万元，同比下降144.92%。股本股东变化截至2026年6月30日，阳光诺和股东户数为7726.0户，较3月31日减少262.0户，减幅为3.28%。该项计提减少合并报表利润总额约6505.21万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663111670","title":"阳光诺和上半年实现营收4.26亿元 创新管线蓄力待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2663111670","media":"中国财富通","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663111670?lang=zh_cn&edition=full","pubTime":"2026-08-29 10:55","pubTimestamp":1787972108,"startTime":"0","endTime":"0","summary":"8月28日，阳光诺和（688621）披露2026年半年报，报告期内，公司实现营收4.26亿元。公司战略转型成效渐显：自研1类创新药STC007（瘙痒）完成对外授权，STC008（肿瘤恶液质）临床推进，多个多肽、小核酸、CAR-T管线进入临床阶段；研发投入占营收的比例升至20.54%，技术平台持续升级。公司坚持“CRO服务+自主新药”双轮驱动，以技术转化沉淀长期价值，创新储备与权益分成模式逐渐构筑起未来增长基石。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=q1xvD6GfAdk%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099997","title":"阳光诺和（688621）发布关于使用部分募集资金向全资子公司增资以实施募投项目的公告，8月28日股价下跌3.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099997","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662099997?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:11","pubTimestamp":1787926301,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，阳光诺和报收于63.1元，较前一交易日下跌3.66%，最新总市值为70.67亿元。近日，北京阳光诺和药物研究股份有限公司披露《关于使用部分募集资金向全资子公司增资以实施募投项目的公告》。公司于2026年8月28日召开第三届董事会第三次会议，审议通过使用部分募集资金向全资子公司成都诺和晟泰生物科技有限公司增资9,000.00万元，用于实施‘创新药研发项目’。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800053970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061943","title":"图解阳光诺和中报：第二季度单季净利润同比下降144.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061943","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662061943?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:20","pubTimestamp":1787912434,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和2026年中报显示，上半年度公司主营收入4.26亿元，同比下降27.81%；归母净利润-2440.0万元，同比下降118.79%；扣非净利润-2507.03万元，同比下降120.95%；其中2026年第二季度，公司单季度主营收入2.29亿元，同比下降36.28%；单季度归母净利润-4503.11万元，同比下降144.92%；单季度扣非净利润-4442.46万元，同比下降144.66%；负债率46.3%，投资收益51.63万元，财务费用677.39万元，毛利率49.19%。财报数据概要请见下图:本文数据来源于阳光诺和2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662663690","title":"阳光诺和(688621)6月30日股东户数0.77万户，较上期减少3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662663690","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662663690?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:42","pubTimestamp":1787910177,"startTime":"0","endTime":"0","summary":"证券之星消息，近日阳光诺和披露，截至2026年6月30日公司股东户数为7726.0户，较3月31日减少262.0户，减幅为3.28%。在医疗服务行业个股中，阳光诺和股东户数低于行业平均水平，截至6月30日，医疗服务行业平均股东户数为4.76万户。从股价来看，2026年3月31日至2026年6月30日，阳光诺和区间跌幅为14.14%，在此期间股东户数减少262.0户，减幅为3.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800040833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176847","title":"每周股票复盘：阳光诺和（688621）实控人转让5%股份完成过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176847","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176847?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:34","pubTimestamp":1786818852,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，阳光诺和报收于65.59元，较上周的64.88元上涨1.09%。本周，阳光诺和8月13日盘中最高价报68.38元。本周关注点公司公告汇总：实控人转让5.00%股份已完成过户登记。公司已收到股权激励对象缴纳的认购款共计23,173,586.04元，并取得验资报告及过户登记确认书。转让后，利虔持股比例由27.59%降至22.59%，受让方持股5.00%。受让方承诺12个月内不减持所获股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659197166","title":"阳光诺和半年报预亏警示：仿创转型下三重经营风险凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2659197166","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659197166?lang=zh_cn&edition=full","pubTime":"2026-08-14 12:00","pubTimestamp":1786680000,"startTime":"0","endTime":"0","summary":"2024 至 2025 年，仿制药药学服务营收从 5.59 亿元降至 3.38 亿元，降幅近 40%，毛利率自 61.37% 腰斩至 32.84%，营收占比大幅缩水。尽管 2025 年创新药研发服务收入 2.48 亿元、毛利率 96.87%，全年新签订单同比增长 13.10%，但新兴业务仍处在培育阶段，营收体量有限，短期内无法填补传统业务收缩形成的收入缺口，主业青黄不接的局面难以快速改善。整体来看，阳光诺和转型创新药赛道贴合行业长期发展方向，但当下同时承受盈利结构脆弱、主业衔接断层、大额资本投入三重压力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-08-14/doc-ininhaiv9472328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659049169","title":"股市必读：阳光诺和新发布《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659049169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659049169?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:39","pubTimestamp":1786642749,"startTime":"0","endTime":"0","summary":"公司公告汇总关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告北京阳光诺和药物研究股份有限公司已完成2025年限制性股票激励计划首次授予部分第一个归属期的股份归属登记，本次归属股票数量为1,032,691股，来源为公司从二级市场回购的A股普通股股票，共有113名激励对象参与归属。本次转让已于2026年8月11日完成过户登记，股份性质为无限售流通股。转让后，利虔持股比例由27.59%降至22.59%，受让方持股5.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197378","title":"阳光诺和（688621）披露2025年限制性股票激励计划首次授予部分第一个归属期归属结果公告，8月12日股价上涨3.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197378","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658197378?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:33","pubTimestamp":1786527206,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，阳光诺和报收于66.25元，较前一交易日上涨3.74%，最新总市值为74.2亿元。近日，北京阳光诺和药物研究股份有限公司披露《关于2025年限制性股票激励计划首次授予部分第一个归属期归属结果的公告》。公告显示，公司已完成2025年限制性股票激励计划首次授予部分第一个归属期的股份归属登记，本次归属股票数量为1,032,691股，来源为公司从二级市场回购的A股普通股股票，共有113名激励对象参与归属。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200030013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791311128883,"stockEarnings":[{"period":"1week","weight":-0.0566},{"period":"1month","weight":0.0309},{"period":"3month","weight":0.2738},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.079},{"period":"ytd","weight":0.1465}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京阳光诺和药物研究股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"7726人(较上一季度减少3.28%)","perCapita":"14496股","listingDate":"2021-06-21","address":"北京市昌平区科技园区双营西路79号院7号楼一层","registeredCapital":"11200万元","survey":" 北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是药物发现、药理药效、药学研究、临床研究、生物分析。公司先后获评国家第五批专精特新“小巨人”企业、北京市高新技术企业、北京市知识产权试点单位、北京市专精特新中小企业等多项资质与荣誉。","listedPrice":26.89},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阳光诺和,688621,阳光诺和股票,阳光诺和股票老虎,阳光诺和股票老虎国际,阳光诺和行情,阳光诺和股票行情,阳光诺和股价,阳光诺和股市,阳光诺和股票价格,阳光诺和股票交易,阳光诺和股票购买,阳光诺和股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}